

ASX Announcement | 20 November 2024 AdAlta Limited (ASX:1AD)

Results of Annual General Meeting

MELBOURNE Australia, 20 November 2024: AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), the clinical stage drug discovery company developing novel protein and cell therapeutic products from its i-body® platform, advises that its Annual General Meeting was held today at 11:00am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the votes received in respect of each resolution are set out in the attached summary.

All resolutions were carried with support of more than 97% of shares voted.

This ASX announcement has been authorised for release by Tim Oldham CEO & Managing Director of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today’s most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer, and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

To learn more, please visit: www.adalta.com.au

For more information



Follow us on [Twitter](#)



Follow us on [LinkedIn](#)

Disclosure of Proxy Votes

AdAlta Limited

Annual General Meeting

Wednesday, 20 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	255,566,630	251,600,758 98.45%	2,725,741 1.07%	84,799	1,240,131 0.49%	352,386,714 99.23%	2,725,741 0.77%	84,799	-
2 Re-election of Director, Dr Paul MacLeman	P	259,101,241	254,690,103 98.30%	3,292,138 1.27%	0	1,119,000 0.43%	355,827,898 99.08%	3,292,138 0.92%	0	Carried
3 Approval of issue of STI Performance Rights to Dr Timothy Oldham, Director of the Company (or his nominee/s)	P	255,526,630	247,611,988 96.90%	6,674,511 2.61%	124,799	1,240,131 0.49%	348,397,944 98.12%	6,674,511 1.88%	124,799	Carried
4 Approval of issue of LTI Options to Dr Timothy Oldham, Director of the Company (or his nominee/s)	P	255,526,630	243,901,976 95.45%	10,384,523 4.06%	124,799	1,240,131 0.49%	344,687,932 97.08%	10,384,523 2.92%	124,799	Carried
5 Approval of Proportional Takeover Provisions	P	259,039,241	256,268,286 98.93%	1,464,449 0.57%	62,000	1,306,506 0.50%	357,593,587 99.59%	1,464,449 0.41%	62,000	Carried
6 ASX Listing Rule 7.1A (Approval of Additional 10% Placement Capacity)	P	259,061,241	251,835,460 97.21%	5,985,650 2.31%	40,000	1,240,131 0.48%	353,094,386 98.33%	5,985,650 1.67%	40,000	Carried

